Last reviewed · How we verify
Terbinafine Tablets
Terbinafine inhibits fungal squalene epoxidase, disrupting ergosterol synthesis and causing fungal cell membrane collapse.
Terbinafine inhibits fungal squalene epoxidase, disrupting ergosterol synthesis and causing fungal cell membrane collapse. Used for Onychomycosis (fungal nail infection), Tinea pedis (athlete's foot), Tinea corporis (ringworm).
At a glance
| Generic name | Terbinafine Tablets |
|---|---|
| Also known as | Lamisil, Terbinafine 250 |
| Sponsor | Oregon Health and Science University |
| Drug class | Allylamine antifungal |
| Target | Squalene epoxidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Terbinafine is a fungistatic and fungicidal agent that selectively inhibits the enzyme squalene epoxidase in the fungal sterol synthesis pathway. By blocking ergosterol production, an essential component of fungal cell membranes, the drug causes membrane instability and cell death. This mechanism is particularly effective against dermatophytes and other fungi causing superficial infections.
Approved indications
- Onychomycosis (fungal nail infection)
- Tinea pedis (athlete's foot)
- Tinea corporis (ringworm)
- Tinea cruris (jock itch)
Common side effects
- Headache
- Gastrointestinal disturbance (nausea, diarrhea, dyspepsia)
- Rash
- Taste disturbance
- Hepatotoxicity (elevated liver enzymes)
- Neutropenia
Key clinical trials
- Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis
- Terbinafine HCl 250 mg Tablet Under Fasting Conditions (PHASE1)
- Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease (PHASE2)
- Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg (PHASE1)
- Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg (PHASE1)
- Terbinafine Treatment of Axial Spondyloarthropathy (EARLY_PHASE1)
- Efficacy and Safety of Terbinafine and Itraconazole (PHASE2, PHASE3)
- Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terbinafine Tablets CI brief — competitive landscape report
- Terbinafine Tablets updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI